Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: Application of a novel pharmacodynamic assay

Authors

Ravi Vij, Washington University School of Medicine in St. Louis
et al

Journal

British journal of haematology

Publication Date

2016

Volume

173

Inclusive Pages

884-895

Document Type

Open Access Publication

DOI

10.1111/bjh.14014

Rights and Permissions

Lee, S. J., Levitsky, K., Parlati, F., Bennett, M. K., Arastu-Kapur, S., Kellerman, L., Woo, T. F., Wong, A. F., Papadopoulos, K. P., Niesvizky, R., Badros, A. Z., Vij, R., Jagannath, S., Siegel, D., Wang, M., Ahmann, G. J. and Kirk, C. J. (2016), Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. Br J Haematol, 173: 884–895. doi:10.1111/bjh.14014 This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use anddistribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Recommended Citation

Vij, Ravi and et al, "Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: Application of a novel pharmacodynamic assay." British journal of haematology. 173, 884-895. (2016).
https://digitalcommons.wustl.edu/open_access_pubs/5830